Vasoactive intestinal peptide shifted the immune environment at the maternal-fetal interface in autoimmune diabetic mice toward tolerance, improving early pregnancy outcomes.
Increased IL-10, TGF-β & Foxp3 at implantation sitesVIP shifted the immune balance from inflammatory to tolerant at the maternal-fetal interface in autoimmune-prone mice
What the researchers found
Vasoactive intestinal peptide (VIP) improved early pregnancy outcomes in non-obese diabetic (NOD) mice by shifting the immune environment at the maternal-fetal interface toward tolerance. In vitro, VIP treatment of implantation sites increased expression of immunosuppressive markers IL-10, TGF-β, and Foxp3 (a marker of regulatory T cells). It also reduced expression of IL-17 and RORγT, markers associated with inflammatory immune responses. Resorption sites (where pregnancies were failing) had lower VIP expression and reduced suppressive markers compared to viable sites. When pregnant NOD mice were injected with VIP on gestational day 6.5, they showed a more even distribution of viable implantation sites with increased IL-10, TGF-β, and Foxp3 expression by day 9.5.
Why it matters
Pregnancy complications in autoimmune conditions like type 1 diabetes often involve the immune system attacking the developing placenta. This study shows that VIP — a naturally occurring peptide — can tip the immune balance at the maternal-fetal interface toward tolerance, potentially protecting pregnancies in autoimmune-prone individuals. It highlights VIP as a candidate for preventing immune-mediated pregnancy loss.
How the study worked
Researchers used NOD mice, a model for autoimmune diabetes. Implantation sites were isolated at gestational day 9.5 and treated with VIP in vitro. Gene and protein expression of cytokines (IL-10, TGF-β, IL-17) and transcription factors (Foxp3, RORγT) were measured using RT-PCR, immunoblotting, and immunohistochemistry. In a parallel experiment, pregnant NOD mice received VIP injections on day 6.5 and outcomes were assessed at day 9.5.
Who was studied
Non-obese diabetic (NOD) pregnant mice
What this study cannot tell us
This is an animal study using NOD mice, which model autoimmune diabetes but don't perfectly replicate human pregnancy complications. The VIP injection was given at a single time point, so the optimal timing and duration of treatment remain unknown. The study focused on early pregnancy (day 6.5–9.5), so later-stage effects were not assessed.
How to read the evidence
This is a preclinical study in NOD mice using both in vitro and in vivo approaches. It provides mechanistic insight but has not been tested in human pregnancy.
When this study was published
Published in 2014 in the American Journal of Reproductive Immunology. VIP's role in reproductive immunology remains an active research area, though clinical translation has been slow.
The bigger picture
Pregnancy loss in autoimmune disease remains a significant clinical challenge. Most treatments focus on broad immunosuppression, which carries its own risks. VIP offers a more targeted approach — promoting regulatory T cells and anti-inflammatory cytokines specifically at the maternal-fetal interface. This connects to the broader field of reproductive immunology, where understanding how the body tolerates a genetically foreign fetus could lead to new therapies for recurrent pregnancy loss.
Questions still open
- Could VIP or VIP analogs reduce pregnancy complications in women with autoimmune conditions?
- What is the optimal timing and dosing for VIP treatment during pregnancy?
- Does VIP have similar immune-modulating effects at the maternal-fetal interface in non-autoimmune pregnancy complications?
Common questions
What is VIP and why is it relevant to pregnancy?
Could VIP be used to treat recurrent miscarriage?
Read the original research
Vasoactive intestinal peptide induces an immunosuppressant microenvironment in the maternal-fetal interface of non-obese diabetic mice and improves early pregnancy outcome.
American journal of reproductive immunology (New York, N.Y. : 1989), 71(2), 120-30
Citation
Hauk, Vanesa; Azzam, Sofía; Calo, Guillermina; Gallino, Lucila; Paparini, Daniel; Franchi, Ana; Ramhorst, Rosanna; Pérez Leirós, Claudia. (2014). Vasoactive intestinal peptide induces an immunosuppressant microenvironment in the maternal-fetal interface of non-obese diabetic mice and improves early pregnancy outcome.. American journal of reproductive immunology (New York, N.Y. : 1989), 71(2), 120-30. https://doi.org/10.1111/aji.12167